[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hcm---hypertrophic-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hcm---hypertrophic-cardiomyopathy":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,75,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100622323","myocardial-perfusion-cmr-for-differentiating-and-characterizing-hypertrophic-cardiomyopathy-phenotypes-100622323",false,"NCT07382128","Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes","MyoPerf-HCM","Inclusion Criteria:\n\n* A confirmed diagnosis of cardiomyopathy with a hypertrophic phenotype, according to current ESC guidelines; or a first-degree relative of a patient with a confirmed diagnosis of cardiomyopathy with a hypertrophic phenotype; or a carrier of a genetic mutation for hypertrophic cardiomyopathy (carriers).\n* Patient with an indication to undergo cardiac magnetic resonance imaging (CMR) according to current ESC guidelines.\n* Age ≥ 18 years\n* Written informed consent obtained\n\nExclusion Criteria:\n\n\\- History of previous myocardial infarction or myocardial revascularization (coronary artery bypass grafting or percutaneous coronary angioplasty) and\u002For evidence of coronary stenosis ≥ 50% on coronary CT scan or invasive coronary angiography.","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","OBSERVATIONAL","This observational study aims to evaluate myocardial perfusion abnormalities using quantitative and qualitative cardiac magnetic resonance (CMR) perfusion imaging in patients with hypertrophic cardiomyopathy (HCM) phenotypes, including sarcomeric and non-sarcomeric HCM, Anderson-Fabry disease (AFD), and cardiac amyloidosis. The study will also include first-degree relatives of affected patients and genetic mutation carriers. By comparing myocardial blood flow and perfusion patterns across these different conditions, the study seeks to identify distinctive perfusion signatures that may improve diagnostic differentiation, support risk stratification, and provide insights into the role of ischemia in fibrosis progression, arrhythmias, and long-term outcomes.",[24,25,26,27],"HCM - Hypertrophic Cardiomyopathy","Anderson Fabry Disease","Cardiac Magnetic Resonance Imaging","Amyloid Cardiomyopathy","RECRUITING","2026-01-26",{"date":31,"type":32},"2026-02-02","ACTUAL",{"date":34,"type":32},"2025-06-01",{"date":36,"type":20},"2027-06-01",{"name":38,"class":39},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":40},"100621559","left-bundle-branch-pacing-in-patients-with-hypertrophic-cardiomyopathy-after-myectomy-100621559","NCT07372196","Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy","LEFTpaceHCM","Inclusion criteria:\n\n* Men and women aged 18 years and older;\n* Patients with post-myectomy HCM who develop LBBB with a QRS complex greater than 130 ms and a high risk of SCD (HCM Risk-SCD ≥ 6%);\n* Signed informed consent to participate in the study;\n\nExclusion criteria:\n\n* Absence of QRS complex morphology consistent with LBBB in LBBB with a positive QRS complex less than 130 ms;\n* Presence of baseline complete RBBB;\n* Heart transplantation or implantation of an LVAD is planned within the next 6 months;\n* Patients with intermediate or low risk of SCD;\n* History of AMI less than three months prior to study inclusion;\n* Acute renal and hepatic failure;\n* Acute infectious diseases;\n* Presence of mental illness;\n* Presence of other illnesses for which life expectancy is less than one year;\n* Patient refusal to participate in the study at any stage;","75 Years",{"count":50,"type":20},30,"INTERVENTIONAL",[53],"NA","Pilot interventional randomized clinical trial to study the efficacy of left bundle branch pacing in patients with hypertrophic cardiomyopathy after myectomy for the prevention of progression of heart failure, prevent the occurrence of life-threatening rhythm disturbances and promote reverse remodeling of the LV.\n\nThe aim of the study is to evaluate the comparative efficacy and safety of implantation of a cardioverter-defibrillator with left bundle branch block pacing and a dual-chamber cardioverter-defibrillator in patients with HCM and complete left bundle branch block after myectomy at high risk of SCD.\n\nObjectives of the study:\n\n1. To analyze the safety of ICD implantation procedures with LBBB pacing in patients with HCM and LBBB after myectomy at high risk of SCD;\n2. To develop a technique for LBBB lead implantation in patients with HCM and LBBB after myectomy;\n3. To conduct a comparative analysis of QRS complex duration data based on ECG data before and after surgery, LV activation time, and pacing threshold based on postoperative programming data;\n4. To conduct a comparative analysis of the functional class of CHF, NT-proBNP, the presence\u002Fabsence of interventricular and intraventricular dyssynchrony, the degree of diastolic dysfunction, LVEF, and LV EDV based on echocardiography data before and 12 months after surgery;\n5. Conduct a comparative analysis of QRS complex duration data based on ECG data, LV activation time, pacing threshold, the presence of recorded episodes of AF, VT, VF, antitachycardia and shock therapy according to programming data at 3, 6, and 12 months after surgery;\n6. Assess quality of life before and 12 months after surgery using the KCCQ-12 questionnaire; 30 patients (15 patients in each group) will be randomly separated into 2 groups. All participants go through ICD programming at 3, 6, and 12 months after myectomy, assessment of left ventricular remodeling based on ECG and echocardiography, NT-proBNP, assessment of quality of life before surgery and 12 months after surgery.",[24,56,57,58,59],"Sudden Cardiac Death","Left Bundle Branch Pacing","ICD","Heart Failure (HF)",[61,62,57,58,63,64],"sudden cardiac death","Hypertrophic Cardiomyopathy","Heart failure","myectomy","2026-01-20",{"date":67,"type":32},"2026-01-28",{"date":69,"type":32},"2025-11-14",{"date":71,"type":20},"2027-07-01",{"name":73,"class":74},"Meshalkin Research Institute of Pathology of Circulation","NETWORK",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":51,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":40},"100615583","effect-of-henagliflozin-on-myocardial-fibrosis-in-non-obstructive-hcm-a-randomized-double-blind-placebo-controlled-trial-using-68ga18f-fapi-petcmr-100615583","NCT07294495","Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga\u002F18F-FAPI PET\u002FCMR","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effect of Henagliflozin on Myocardial Fibrosis Burden in Patients With Non-Obstructive Hypertrophic Cardiomyopathy Using 68Ga\u002F18F-FAPI PET\u002FCMR","Inclusion Criteria:\n\n1. Aged 18 years or older, regardless of gender.\n2. Meets the diagnostic criteria for non-obstructive hypertrophic cardiomyopathy (HCM):\n\n   * Confirmed diagnosis of HCM by cardiac magnetic resonance (CMR) or echocardiography (left ventricular wall thickness ≥15 mm, or ≥13 mm in the presence of a family history of HCM).\n   * Exclusion of patients in whom left ventricular hypertrophy is primarily attributable to hypertensive heart disease, as assessed by a cardiology specialist based on clinical and imaging evidence.\n   * Exclusion of other identifiable causes of secondary myocardial hypertrophy (e.g., valvular heart disease, storage cardiomyopathies).\n   * Left ventricular outflow tract (LVOT) gradient \\\u003C30 mmHg at rest or under provocation, as assessed by echocardiography or CMR.\n3. Willing to undergo FAPI PET\u002FCMR examination and complete imaging evaluations.\n4. Baseline FAPI PET\u002FCMR scan shows positive FAPI uptake: myocardial FAPI target-to-background ratio (TBR) ≥1.3, using the ascending aorta blood pool as the background reference.\n5. Capable of understanding and signing the informed consent form, and agrees to participate in the study, accept randomization, and comply with follow-up visits.\n6. New York Heart Association (NYHA) functional class I-III.\n\nExclusion Criteria:\n\n1. Significant left ventricular outflow tract obstruction (resting or provoked LVOT pressure gradient ≥30 mmHg).\n2. Coexistence of other identifiable causes of myocardial hypertrophy, including:\n\n   * Predominant or persistent hypertensive heart disease;\n   * Severe aortic stenosis or other significant valvular heart disease;\n   * Infiltrative or storage cardiomyopathies (e.g., Fabry disease, amyloidosis);\n   * Ischemic heart disease (e.g., severe coronary artery disease).\n3. Overt decompensated heart failure or NYHA functional class IV.\n4. Unstable, serious arrhythmias (e.g., sustained ventricular tachycardia, recent cardioversion for atrial fibrillation).\n5. Recent (within 3 months) cardiac surgery or interventional procedure.\n6. ALT or AST \\>3 times the upper limit of normal (ULN), OR total bilirubin (Tbil) \\>2 times ULN, OR ketonuria\u002Fketonemia, OR eGFR \\\u003C30 mL\u002Fmin\u002F1.73m², OR creatine kinase (CK) \\>3 times ULN.\n7. Concurrent other severe systemic disease with a life expectancy of less than 1 year.\n8. Pregnant or breastfeeding women.\n9. History of allergy to the study drug or any contraindication to its use.\n10. Any other condition deemed by the investigator to make the subject unsuitable for participation.",{"count":83,"type":20},150,[53],"his is a single-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of Henagliflozin (an SGLT2 inhibitor) on myocardial fibrosis burden in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The study will use 68 68 Ga\u002F 18 18 F-FAPI PET\u002FCMR imaging to quantitatively assess changes in active fibroblast activity after 6 months of treatment. A total of 150 eligible adult patients with nHCM (FAPI-positive at baseline, NYHA class I-III) will be enrolled and randomized in a 1:1 ratio to either the Henagliflozin group (10 mg once daily) or the placebo group for a 6-month treatment period. The primary endpoint is the change in myocardial FAPI target-to-background ratio (ΔTBR) at 6 months. Secondary endpoints include changes in FAPI SUVmax, FAPI burden percentage (FAV%), cardiac structure and function parameters, 6-minute walk distance, NYHA classification, NT-proBNP levels, and quality-of-life scores. Exploratory analyses will assess clinical events over 12 months, such as heart failure hospitalization, atrial fibrillation, ventricular arrhythmias, and cardiovascular death. The study employs stratified block randomization based on baseline FAPI burden, central randomization and blinding via IWRS, independent core laboratory imaging evaluation, and an intention-to-treat analytical approach. It aims to provide early evidence for the anti-fibrotic effect of Henagliflozin in nHCM and to validate FAPI-PET\u002FCMR as an imaging biomarker for fibrosis activity.",[24],[88,89,62],"PET\u002FMR","FAPI","NOT_YET_RECRUITING","2025-12-08",{"date":93,"type":32},"2025-12-19",{"date":95,"type":20},"2026-01-07",{"date":97,"type":20},"2028-12-31",{"name":99,"class":39},"Shanghai East Hospital",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":108,"enrollmentInfo":109,"targetDuration":111,"studyType":21,"phases":4,"briefSummary":112,"conditions":113,"keywords":121,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":40},"100382854","dzhk-torch-plus-is-a-registry-for-patients-with-cardiomyopathies-and-serves-as-source-for-cardiovascular-research-studies-100382854","NCT04265040","DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies","TranslatiOnal Registry for CardiomyopatHies (TORCH) - Plus as Part of the German Centre for Cardiovascular Research (DZHK)","TORCH-Plus","Inclusion Criteria:\n\n* Non-ischemic structural cardiomyopathies\n* Age ≥ 18 or ≤ 80 years\n* The patient is able to understand the declaration of consent and to sign it dated\n* At least one of the following diagnoses depending on the specific TORCH-\n\nPlus inclusion \u002F exclusion - SOP:\n\nDilated Cardiomyopathy (DCM)\n\n* family \u002F genetic\n* inflammatory \u002F persistent myocarditis\n* idiopathic (after exclusion secondary cause)\n* left sided systolic dysfunction (EF ≤ 45%)\n\nLeft ventricular hypertrophy\n\n* sarcomere hypertrophic cardiomoypathia (HCM, HOCM)\n* amyloid (AL: light chains, TTR: transthyretin, wild type)\n\nLeft ventricular non-compaction cardiomyopathy (LVNC)\n\nArrhythmogenic right ventricular cardiomyopathy (ARVC \u002F D)\n\nExclusion Criteria:\n\nThe following exclusion criteria have been defined and must be taken from the TORCH-Plus specific inclusion \u002F exclusion - SOP in detail:\n\n* Age: \\\u003C18 years or\\> 80 years\n* Patient has other (cardiac) previous illnesses:\n\n  * uncontrollable arterial hypertension\n  * primary pulmonary arterial hypertension\n  * radiation therapy in the chest area\n  * addiction (drug or alcohol abuse)\n  * life expectancy \\\u003C1 year due to non-cardiological pre-existing conditions\n  * significant heart valve disease\n  * ischemic diseases and severe congenital heart diseases (including VSD, Fallot tetralogy, Ebstein anomaly)\n  * chemotoxic cardiomyopathy\n  * condition after myocarditis\n  * combination of several traditional risk factors (e.g. hypertension and diabetes mellitus)\n  * advanced chronic non-cardiac disease (e.g. chronic hepatitis or HIV)\n  * Tachymyopathy","80 Years",{"count":110,"type":20},2040,"4 Years","The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP). As a multi-center German cardiomyopathy registry, TORCH has been prospectively admitting patients since December 2014. 2,300 patients were recruited as planned. Taken together, patient data showed that the prevalence of these diseases is much higher in men than in women, atrial fibrillation is common in all forms of CMPs as well as rare forms of disease indicate a higher risk and higher morbidity.\n\nThis DZHK TORCH register is now to be expanded with a second phase (DZHK TORCH-Plus). The second phase DZHK TORCH-Plus consists of 4 main modules: 1. \"Clinical phenotyping, follow-up \\& biosampling\" 2. \"Genomics\", 3. \"Inflammation\" and 4. \"Biomarker\". The central aims are 1) to significantly increase the number of probands (n = 4340) in order to better address the different types of CMPs, especially patients with rare CMP forms such as LVNC and ARVC or with probably molecularly explainable cardiomyopathies (familial DCM), 2) to prolong the longitudinal with a further follow-up to achieve sufficient events and thereby derive clinical recommendations for risk assessment, 3) to increase the number of probands with state-of-the-art phenotyping, 4) to pinpoint the effect of myocardial inflammation, fibrosis, gender and to determine or predict genotypes based for outcome, 5) to validate novel biomarkers developed in other DZHK studies, and 6) to foster active cooperation with international CMP registries and partners from industry.",[114,115,24,116,117,118,119,120],"Non-ischemic Cardiomyopathy","DCM - Dilated Cardiomyopathy","HOCM - Hypertrophic Obstructive Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy","Left Ventricular Noncompaction Cardiomyopathy","Amyloidosis","Inflammatory Cardiomyopathy",[122],"Cardiomyopathies, registry, data, biomaterial, genetics","2023-11-29",{"date":125,"type":32},"2023-11-30",{"date":127,"type":32},"2020-08-18",{"date":129,"type":20},"2027-12",{"name":131,"class":39},"University Hospital Heidelberg"]